For research use only. Not for therapeutic Use.
(S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer’s disease or schizophrenia[1][2].
| Catalog Number | I041403 |
| Synonyms | (3S)-3-[6-(4-methylphenyl)pyridin-3-yl]oxy-1-azabicyclo[2.2.2]octane |
| Molecular Formula | C19H22N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m1/s1 |
| InChIKey | NPDLTEZXGWRMLQ-LJQANCHMSA-N |
| SMILES | CC1=CC=C(C=C1)C2=NC=C(C=C2)OC3CN4CCC3CC4 |
| Reference | [1]. Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172(5):1292-304. [2]. Mazurov A, et al. Nicotinic acetylcholine receptor modulators[J]. Small Molecule Therapeutics for Schizophrenia, 2015: 213-253. |
